Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash Flows from Operating Activities:
Net loss from continuing operations	$ (6,857,700)	$ (7,137,667)
Loss from discontinued operations, net of tax	(1,252,276)
Gain on sale of discontinued operations	1,534,479	0
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on sale of discontinued operations	(1,534,479)
Stock-based compensation	375,169	367,539
Depreciation and amortization of intangible assets	47,061	50,375
Amortization of right of use assets	68,779	71,621
Amortization of debt discount	19,549	8,300
Change in fair value of forward purchase agreement	4,280,314
Change in fair value of derivative liabilities		3,870,158
Changes in operating assets and liabilities:
Prepaid expenses	597,108	49,603
Inventory	(113,872)
Assets available for sale	4,662,980
Other current assets		28,175
Accounts payable	(321,816)	599,520
Accrued expenses and other liabilities	(1,259,808)	668,664
Lease liability	(70,399)	(63,460)
Accrued interest		531,035
Liabilities available for sale	(2,389,343)
Net cash used in operating activities	(2,214,254)	(956,137)
Cash flows from investing activities
Cash paid in AxoBio Disposition	(748,796)
Purchase of property and equipment		(30,470)
Net cash used in investing activities	(748,796)	(30,470)
Cash Flows from Financing Activities:
Proceeds from issuance of Common Stock, net of costs	2,687,225
Proceeds from issuance of loans	31,538	848,500
Payment of loans	(469,899)
Proceeds from common stock option exercises		25,878
Net cash provided by financing activities	2,248,864	874,378
Net decrease in cash	(714,186)	(112,229)
Cash - beginning of the period	2,912,461	128,149
Cash - end of the period	2,198,275	15,920
Supplemental cash flow information:
Interest paid	14,830
Non-cash financing activity:
Net assets sold in AxoBio Acquisition	21,921,697
Fair value of shares received in AxoBio Disposition	23,456,179
Common Stock issued in connection with conversion of Promissory Notes	$ 848,500
Accrued Legacy Series A preferred stock dividends		151,855
Accrued Legacy Series C-1 preferred stock dividends		37,639
Accrued Legacy Series C-2 preferred stock dividends		437,151
Warrants issued in connection with promissory notes		55,062
Unpaid deferred offering costs		$ 923,222